LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - LifeStance Health Group reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and an improvement from a loss of $0.13 per share a year ago, resulting in an earnings surprise of 14.29% [1] - The company posted revenues of $312.33 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 2.40%, and showing an increase from $259.58 million in the same quarter last year [2] - LifeStance Health has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] Group 2 - The stock has underperformed, losing about 29.6% since the beginning of the year, while the S&P 500 has gained 9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The estimate revisions trend for LifeStance Health is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $301.26 million, and for the current fiscal year, it is -$0.26 on revenues of $1.22 billion [7] - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]